Treatment - The Bloodline with Blood Cancer United Podcast

Curious about CAR T-cell therapy? We went straight to the source for answers.

In this episode, the LLS Patient Education team visited The University of Miami Sylvester Cancer Center to meet with Dr. Trent Wang. He answered some of the most frequently asked questions from our patients and caregivers about this innovative cancer treatment – from who’s eligible and what to expect, to side effects, caregiver roles, and exciting future developments.

Mentioned on this episode: 

Additional LLS Support Resources: 

Supported by Bristol Myers Squibb; Johnson & Johnson & Legend Biotech; and Kite, a Gilead Company.

The post CAR T-cell Therapy: Your Questions Answered first appeared on The Bloodline with Blood Cancer United Podcast.

Acute myeloid leukemia (AML) is one of the most aggressive blood cancers—but science is making real progress. In this episode, Dr. Eytan Stein of Memorial Sloan Kettering breaks down what makes AML so challenging to treat, how it’s classified, and the latest therapies changing the outlook for patients. From combination therapies and menin inhibitors to future research on CAR T-cell therapy and bispecifics, this is a hopeful, expert-led look at the future of AML treatment.

Mentioned on this episode: 

Additional LLS Support Resources: 

Supported by Abbvie Inc.; Astellas Pharma US Inc.; Genentech, A Member of the Roche Group; and Kura Oncology, Inc.

The post Understanding AML: The Challenges, The Progress, The Hope first appeared on The Bloodline with Blood Cancer United Podcast.

In this episode, we sit down with Dr. Cesar Rodriguez of Mount Sinai Hospital in New York, NY to discuss the evolving landscape of myeloma treatment. Groundbreaking innovations are bringing new hope to patients and caregivers. Dr. Rodriguez breaks down the latest advancements in immunotherapy, including CAR T-cell therapy and bispecific antibodies. Hear how researchers and physicians are working to make myeloma into a manageable, long-term disease, while ultimately searching for a cure.

Mentioned on this episode: 

Additional LLS Support Resources: 

Supported by Abbvie Inc.; Genentech, A Member of the Roche Group; and Johnson & Johnson.

The post Hope in Myeloma: The Road to Long-Term Survival first appeared on The Bloodline with Blood Cancer United Podcast.

A Cutaneous T-cell Lymphoma (CTCL) diagnosis can raise many questions, from understanding symptoms to exploring treatment options.  In this episode, we talk to Dr. Francine Foss of Yale University to break down what CTCL is, how to manage side effects, and the latest advancements in treatment—including promising immunotherapies like CAR T-cell therapy and bispecific antibodies.  We also discuss the critical role of clinical trials in shaping the future of CTCL care.  

Mentioned on this episode: 

Additional LLS Support Resources: 

Supported by Kyowa Kirin, Inc.

The post Cutaneous T-Cell Lymphoma (CTCL): From Diagnosis to Innovation first appeared on The Bloodline with Blood Cancer United Podcast.

In this episode, we sit down with Dr. Bilal Abid from University of Texas Health Science Center in Houston to discuss how healthcare disparities have an effect on cancer care — especially when it comes to cutting-edge treatments such as stem cell transplantations and CAR T-cell therapy. We discuss how race, socioeconomic status, education, and geographic location can determine a patient’s access to cancer care. With travel, insurance, and systemic barriers in the mix, we explore what patients can do to navigate these challenges, and how treatment centers and policymakers are contributing to ensure equitable access to care for all patients.

Mentioned on this episode: 

Additional LLS Support Resources: 

Supported by Genentech, A Member of the Roche Group.

The post Impact of Disparity: Navigating Treatment Equality in Cancer Care first appeared on The Bloodline with Blood Cancer United Podcast.

A stem cell transplant for blood cancer is just the beginning – what may come next for the patient can be a complex journey. In this episode, Dr. Alison Loren of the University of Pennsylvania discusses graft-vs-host disease (GVHD), a possible complication of transplantation – exploring the latest advancements in treatment and how patients and caregivers can navigate the challenges ahead.

Mentioned on this episode: 

Additional LLS Support Resources: 

The post Beyond the Transplant: Navigating Graft-vs-Host Disease (GVHD) first appeared on The Bloodline with Blood Cancer United Podcast.

Explore the cutting-edge of oncology as we delve into the revolutionary world of CAR T-cell therapy, a more recent medical advancement in the fight against blood cancer.  

Join our conversation with Dr. Marco Davila of Roswell Park Comprehensive Cancer Center in Buffalo, NY, as he highlights the significant impact CAR T-cell therapy has made on treating various blood cancers. Dr. Davila discusses the current uses of this therapy and gives us a look at the ongoing clinical trials that are broadening the horizons of this innovative treatment. 

Mentioned on this episode: 

Additional LLS Support Resources: 

Support for this episode provided by Bristol Myers Squibb; Johnson & Johnson & Legend Biotech; Kite, a Gilead Company; and Novartis Pharmaceuticals Corp.

The post Cellular Revolution: CAR T-cell Therapy first appeared on The Bloodline with Blood Cancer United Podcast.

The fight to effectively treat and cure the complex disease of acute myeloid leukemia (AML) continues.

In this episode, we speak to Dr. Elie Traer, Dr. Karin Rodland and Dr. Lee Greenberger about an exciting new study for AML. The doctors share about a longtime collaboration between Oregon Health & Science University (OHSU) and Pacific Northwest National Laboratory (PNNL) using patient samples from LLS’s Beat AML Master Clinical Trial to further understand the proteins on the cancer cells, resulting in the development of more targeted treatments for AML patients.  

Mentioned on this episode: 

Additional LLS Support Resources: 

Support for this episode provided by: Abbvie Inc. and Genentech, Inc. & Biogen.

The post Visions of Hope: Continuing to Beat AML first appeared on The Bloodline with Blood Cancer United Podcast.

“If you have a rare disease, it’s not rare to you.”

In this episode, Dr. Naveen Pemmaraju of MD Anderson Cancer Center in Houston, TX, sheds light on the latest treatment advancements for myelofibrosis. The pace of scientific discovery for rare diseases is moving at a fast rate, resulting in better outcomes for myelofibrosis patients.

*This episode was recorded on Rare Disease Day, February 29, 2024

Mentioned on this episode: 

Additional LLS Support Resources: 

Support for this episode provided by: GSK plc.

The post Hope for a Rare Disease: Myelofibrosis first appeared on The Bloodline with Blood Cancer United Podcast.

Remarkable progress has been made in the treatment of myeloma over the past decade, giving patients and families much hope for the future. In this episode, we speak to Dr. Nishi Shah of Montefiore Einstein Comprehensive Cancer Center in New York City. While the wide variety of therapies available to patients are discussed, this episode also focuses on the newest, cutting-edge therapies for myeloma, such as CAR T-cell therapy and bispecific antibodies.  

Mentioned on this episode: 

Additional LLS Support Resources: 

Support for this episode provided by: AbbVie Inc.; Genentech, Inc. & Biogen; and Johnson & Johnson.

The post How New Therapies Are Changing The Future of Myeloma first appeared on The Bloodline with Blood Cancer United Podcast.